Manzoli A, Patti G, D'Ambrosio A, Montesanti R, Calabrese V, Abbate A, Gioia G, Di Sciascio G
Dipartimento di Scienze Cardiovascolari, Università Campus Bio-Medico, Roma, Italia.
Clin Ter. 2001 Sep-Oct;152(5):307-13.
Statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) are widely used for the treatment of hypercholesterolemia. They reduce LDL levels more than other lipid-lowering drugs. Moreover, they are effective in raising HDL and even in reducing triglyceride levels. Statins have an excellent tolerability and safety. Clinical trials in patients with and without ischemic heart disease and with and without high cholesterol levels have demonstrated that statins significantly reduce the relative risk of major coronary events and of total mortality. Other mechanisms independent of LDL lowering may play an important role in the clinical benefits conferred by these drugs and may broaden their therapeutic indications from lipid-lowering to antiatherogenic agents.
他汀类药物（3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂）被广泛用于治疗高胆固醇血症。与其他降脂药物相比，它们能更有效地降低低密度脂蛋白（LDL）水平。此外，它们在升高高密度脂蛋白（HDL）甚至降低甘油三酯水平方面也有效果。他汀类药物具有出色的耐受性和安全性。在患有和未患有缺血性心脏病以及胆固醇水平高和不高的患者中进行的临床试验表明，他汀类药物能显著降低主要冠状动脉事件和总死亡率的相对风险。这些药物带来临床益处的过程中，其他不依赖于降低LDL的机制可能发挥重要作用，并且可能将其治疗适应症从降脂药物拓宽到抗动脉粥样硬化药物。
